Combatting mucosal melanoma: recent advances and future perspectives
- PMID: 30459941
- PMCID: PMC6240847
- DOI: 10.2217/mmt-2018-0003
Combatting mucosal melanoma: recent advances and future perspectives
Abstract
Mucosal melanomas are a rare subtype of melanoma and are associated with a particularly poor prognosis. Due to the rarity of the diagnosis, and the pace with which the management of cutaneous melanoma has evolved over recent years, there is little good evidence to guide management and evidence-based clinical guidelines are still in development in the UK. In this review we provide an overview of the management of mucosal melanoma, highlighting the critical differences between cutaneous and mucosal melanomas, before examining recent advances in the systemic treatment of this disease and likely future directions.
Keywords: imatinib; ipilimumab; mucosal melanoma; nivolumab; pembrolizumab.
Conflict of interest statement
Financial & competing interests disclosure M Payne discloses funding for attendance at conferences, speakers’ fees, and honoraria for participation in advisory boards from GSK, BMS, Novartis, Incyte, and MSD. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Similar articles
-
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21. Eur J Cancer. 2019. PMID: 31445199 Clinical Trial.
-
Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.Tohoku J Exp Med. 2019 May;248(1):37-43. doi: 10.1620/tjem.248.37. Tohoku J Exp Med. 2019. PMID: 31105123
-
Targeted Therapy and Immunotherapy for Melanoma in Japan.Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8. Curr Treat Options Oncol. 2019. PMID: 30675668 Free PMC article. Review.
-
Mucosal Melanoma: a Literature Review.Curr Oncol Rep. 2018 Mar 23;20(3):28. doi: 10.1007/s11912-018-0675-0. Curr Oncol Rep. 2018. PMID: 29569184 Review.
-
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.J Clin Oncol. 2017 Jan 10;35(2):226-235. doi: 10.1200/JCO.2016.67.9258. Epub 2016 Nov 7. J Clin Oncol. 2017. PMID: 28056206 Free PMC article.
Cited by
-
Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report.Front Oncol. 2024 Mar 14;14:1301424. doi: 10.3389/fonc.2024.1301424. eCollection 2024. Front Oncol. 2024. PMID: 38549929 Free PMC article.
-
Multidisciplinary approach and treatment of acral and mucosal melanoma.Front Oncol. 2024 Feb 26;14:1340408. doi: 10.3389/fonc.2024.1340408. eCollection 2024. Front Oncol. 2024. PMID: 38469235 Free PMC article. Review.
-
Malignant melanoma of gastrointestinal tract on 18F-FDG PET/CT: three case reports.Am J Nucl Med Mol Imaging. 2023 Dec 25;13(6):279-288. eCollection 2023. Am J Nucl Med Mol Imaging. 2023. PMID: 38204606 Free PMC article.
-
Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.Int J Mol Sci. 2023 Dec 8;24(24):17282. doi: 10.3390/ijms242417282. Int J Mol Sci. 2023. PMID: 38139110 Free PMC article. Review.
-
A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options.Sci Adv. 2023 Oct 27;9(43):eadg6686. doi: 10.1126/sciadv.adg6686. Epub 2023 Oct 27. Sci Adv. 2023. PMID: 37889972 Free PMC article.
References
-
- UK CRUK. Skin cancer incidence statistics. www.cancerresearchuk.org/health-professional/cancer-statistics
-
- Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83(8):1664–1678. - PubMed
-
- Furney SJ, Turajlic S, Stamp G, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J. Pathol. 2013;230(3):261–269. - PubMed
-
- Lian B, Cui CL, Zhou L, et al. The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann. Oncol. 2017;28(4):868–873. - PubMed
Publication types
LinkOut - more resources
Full Text Sources